Management ChangeMay 11, 2026, 04:13 PM
AnaptysBio Appoints Christopher M. Murphy as CFO; Owen Hughes as Director
AI Summary
AnaptysBio, Inc. announced the appointment of Christopher M. Murphy as Chief Financial Officer, effective May 11, 2026. Mr. Murphy will receive a monthly consulting fee of $42,916.66, an annual target cash bonus of up to 40% of his fees, and an equity grant worth $1,750,000 in restricted stock units. Additionally, Owen Hughes was appointed as a Class I director, effective May 11, 2026, and will receive an initial grant of 11,250 restricted stock units.
Key Highlights
- Christopher M. Murphy appointed Chief Financial Officer, effective May 11, 2026.
- Mr. Murphy to receive monthly consulting fees of $42,916.66.
- Annual target cash bonus opportunity of up to 40% of total annual consulting fees.
- Equity grant worth $1,750,000 in restricted stock units, vesting over four years.
- Severance includes 9-12 months of fees and full equity vesting under certain conditions.
- Owen Hughes appointed as a Class I director, effective May 11, 2026.
- Mr. Hughes received an initial grant of 11,250 restricted stock units, vesting over three years.
Price Impact
More from ANAB